Advertisement

Topics

Allergic Conjunctivitis - Pipeline Review, H1 2015

05:00 EDT 8 Jun 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Allergic Conjunctivitis - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-04-28. This 71-page report is available in PDF from $2000.

Allergic Conjunctivitis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Allergic Conjunctivitis - Pipeline Review, H1 2015’, provides an overview of the Allergic Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Allergic Conjunctivitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Allergic Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of…

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Conjunctivitis - Overview 9
Pipeline Products for Allergic Conjunctivitis - Comparative Analysis 10
Allergic Conjunctivitis - Therapeutics under Development by Companies 11
Allergic Conjunctivitis - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Allergic Conjunctivitis - Products under Development by Companies 15
Allergic Conjunctivitis - Companies Involved in Therapeutics Development 16
Alcon, Inc. 16
Allergan, Inc. 17
Celsus Therapeutics Plc 18
Eleven Biotherapeutics Inc. 19
Griffin Discoveries BV 20
Laila Pharmaceuticals Pvt. Ltd. 21
NicOx S.A. 22
Ocular Therapeutix, Inc. 23
Ohr Pharmaceutical Inc. 24
Oxagen Limited 25
Sun Pharma Advanced Research Company Ltd. 26
Xencor, Inc. 27
Allergic Conjunctivitis - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
AGN-229666 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AL-53817 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
cetirizine hydrochloride - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dexamethasone acetate SR - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Drugs for Allergic Conjunctivitis - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
GD-134 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
isunakinra - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
KBP-7306 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
LP-00209 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
OC-2417 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
OC-459 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
OPX-1 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Antagonize Histamine H1/H4 Receptor for Ophthalmology and Asthma - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SUN-0597 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
XmAb-7195 - Drug Profile 54
Product…

For more information open Allergic Conjunctivitis - Pipeline Review, H1 2015.

SKU: GMDHC6612IDB

Original Article: Allergic Conjunctivitis - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Allergic Conjunctivitis - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...